RE:RE:Another lawsuit? Does anyone know how many agreements they already have?
Novartis is a massive player in the market? They will probably settle with a substantial royalty agreement.
I don't see MBX needing to sell the technology to Novartis.
Commercialization Strategy
Microbix has chosen to license the VIRUSMAX technology on a regional basis, starting with countries where vaccine supply is most deficient. Licenses are initially available to local domestic manufacturers, multinational manufacturers with facilities in the licensing region, and/or start up manufacturers’ facilities. The terms for such licenses are structured to include upfront and royalty payments.